Enrollment for additional phase I trial of HPV-vaccine

ORYX's vaccine in addition to chemotherapy in HPV-associated cancers

16-Sep-2015 - ORYX announced that first patients have been treated in an additional Phase I clinical trial with VicOryx, a therapeutic vaccine to treat p16INK4a overexpressing Human Papilloma Virus (HPV) positive cancer patients, in combination with standard cisplatin-based chemotherapy. The patients have ...

ORYX' Oncolytic Virus ParvOryx Successfully Completes Phase I/IIa Trial to Treat Glioblastoma Multiforme

16-Jun-2015 - ORYX announced the successful completion of the Phase I/IIa trial ParvOryx with the oncolytic parvovirus H1 to treat patients with progressive primary or recurrent glioblastoma. The open label, single center trial included 18 patients (UICC Stage IV), who showed recurrent or progressive disease ...

ORYX Presents Positive Phase I/IIa Data with Therapeutic Vaccine MicOryx

04-Jun-2015 - ORYX reported positive Phase I/IIa clinical trial results of therapeutic vaccine MicOryx to treat advanced microsatellite instable (MSI-H) colorectal cancer at the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO).The MicOryx vaccine was evaluated in the open label, single ...

ORYX Successfully Completes Phase I/IIa Trial to Treat HPV-Associated Cancers

11-Mar-2015 - ORYX announced the successful completion of a Phase I/IIa trial of the therapeutic vaccine VicOryx to treat p16INK4a-overexpressing HPV- (Human Papilloma Virus-) positive cancer patients in an open label, single center trial that included 26 patients. Inclusion criteria for the trial were a ...

ORYX' Therapeutic Vaccine MicOryx Successfully Completes Phase I/IIa Trial to Treat MSH-H Colorectal Cancer

05-Mar-2015 - ORYX announced the successful completion of a Phase I/IIa trial of the therapeutic vaccine MicOryx to treat advanced microsatellite instable (MSI-H-) colorectal cancer patients in an open label, single center trial that included 22 patients (UICC stage III or IV), who had received standard ...